Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has developed EMBARK, a transdiagnostic psychotherapy model, and will be co-sponsoring an upcoming trial designed for frontline clinicians experiencing COVID-related distress. Cybin announced that the randomized, placebo-controlled trial will evaluate psychedelic-assisted psychotherapy with psilocybin in the treatment of symptoms of depression, anxiety, burnout and post-traumatic stress among doctors, nurses and healthcare professionals on the frontlines of COVID-19. EMBARK is a groundbreaking psychotherapy model that integrates leading clinical approaches aimed at promoting supportive healing with psychedelic medicine. Cybin is collaborating with a University of Washington team, led by Dr. Anthony Back, in sponsoring the trial. In the announcement, the company noted that the nation’s doctors, nurses and clinicians have been shouldering the burden of COVID-19 by taking care of the sickest COVID-19 patients and, as a result, have been experiencing high levels of anxiety, depression and burnout. “For more than a year now, frontline clinicians and healthcare professionals have made immeasurable sacrifices to protect public health in their communities,” said Cybin CEO Doug Drysdale in the press release. “We consider it an honor and our duty to now help support their own healing processes, post-COVID-19. We are also delighted and proud to launch EMBARK, a groundbreaking psychotherapy model aimed at delivering best-practice, supportive healing in conjunction with psychedelic therapeutics. We look forward to working with and supporting Dr. Anthony Back on this important program.”
To view the full press release, visit https://ibn.fm/Bezlj
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics for mental illness and addiction by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.